Skip to content

Monitoring of Effecacy and Adverse Effects of Immunotherapy by breath analysis with Nanose

Monitoring of Effecacy and Adverse Effects of Immunotherapy by breath analysis with Nanose

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042185
Enrollment
Unknown
Registered
2021-01-15
Start date
2021-01-04
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

primary tumors group vs healthy control group:Nil

Sponsors

Anhui Provincial Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, gender is not limited. 2. Primary criteria for the determination of primary tumors. 3. Total bilirubin <= 1.5 x UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (SGPT) <= 2.5 xUNL. 4. Patients have no smoking or drinking for nearly a week. 5. All patients should be informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients without self-knowledge ability. 2. Simultaneously combine with a malignant tumor other than a malignant tumor. 3. Combined with other diseases, such as diabetes, hyperlipidemia, severe hypertension, kidney disease, hyperthyroidism,uncontrolled psychosis; any acute disease symptoms (respiratory inflammatory diseases, active infections) occurred in the past 2 weeks. 4. In the past 2 weeks, drugs that affect metabolism, such as antibiotics (penicillins, erythromycin), hormones (deoxycortisol,dexamethasone), non-steroidal anti-inflammatory drugs (aspirin, granulitis), were used. 5. Previously received radiotherapy, surgery or interventional therapy. 6. There is a significant abnormality in the ventilation of the lungs. 7. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Volatile organic compounds, VOCs;

Countries

China

Contacts

Public ContactHu Liu

Anhui Provincial Cancer Hospital

drliuhu@yahoo.com+86 13866175691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026